PURPOSE: Some women with early-stage breast cancer are at higher risk of recurrence and can benefit from chemotherapy. We describe patterns of referral, receipt, and completion of chemotherapy among older women at high risk of recurrence. PATIENTS AND METHODS: A total of 2,124 women age 65 years or older who were diagnosed with early-stage breast cancer between 1990 and 1994 and 1996 to 1999 were included; 1,090 of these were at high risk of recurrence. We reviewed medical records to categorize chemotherapy outcomes as follows: did not discuss or were not referred to a medical oncologist (n = 133); discussed and/or referred to a medical oncologist but received no chemotherapy (n = 742); received an incomplete chemotherapy course (n = 29), or received a completed chemotherapy course (n = 186). RESULTS: Overall, 19.7% of high-risk women received any chemotherapy, and 86.5% of these women completed their chemotherapy courses. Just greater than 10% of high-risk women did not have a discussion about chemotherapy as part of breast cancer treatment documented in the medical record; these women also received fewer diagnostic assessments of their initial tumors. CONCLUSION: Individuals who receive chemotherapy for early-stage breast cancer are a select subgroup of patients at high risk of recurrence. This study identifies characteristics of women who were referred for and who received chemotherapy, and this study plays an important role in understanding generalizability of studies that examine chemotherapy treatment effectiveness. Outcomes after breast cancer could continue to be improved with increased receipt of chemotherapy among older women at high risk of breast cancer recurrence.
PURPOSE: Some women with early-stage breast cancer are at higher risk of recurrence and can benefit from chemotherapy. We describe patterns of referral, receipt, and completion of chemotherapy among older women at high risk of recurrence. PATIENTS AND METHODS: A total of 2,124 women age 65 years or older who were diagnosed with early-stage breast cancer between 1990 and 1994 and 1996 to 1999 were included; 1,090 of these were at high risk of recurrence. We reviewed medical records to categorize chemotherapy outcomes as follows: did not discuss or were not referred to a medical oncologist (n = 133); discussed and/or referred to a medical oncologist but received no chemotherapy (n = 742); received an incomplete chemotherapy course (n = 29), or received a completed chemotherapy course (n = 186). RESULTS: Overall, 19.7% of high-risk women received any chemotherapy, and 86.5% of these women completed their chemotherapy courses. Just greater than 10% of high-risk women did not have a discussion about chemotherapy as part of breast cancer treatment documented in the medical record; these women also received fewer diagnostic assessments of their initial tumors. CONCLUSION: Individuals who receive chemotherapy for early-stage breast cancer are a select subgroup of patients at high risk of recurrence. This study identifies characteristics of women who were referred for and who received chemotherapy, and this study plays an important role in understanding generalizability of studies that examine chemotherapy treatment effectiveness. Outcomes after breast cancer could continue to be improved with increased receipt of chemotherapy among older women at high risk of breast cancer recurrence.
Authors: Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Sharon H Giordano; Zhigang Duan; Yong-Fang Kuo; Gabriel N Hortobagyi; James S Goodwin Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Marianne Ulcickas Yood; Cynthia Owusu; Diana S M Buist; Ann M Geiger; Terry S Field; Soe Soe Thwin; Timothy L Lash; Marianne N Prout; Feifei Wei; Virginia P Quinn; Floyd J Frost; Rebecca A Silliman Journal: J Am Coll Surg Date: 2007-10-03 Impact factor: 6.113
Authors: Linda C Harlan; Limin X Clegg; Jeffrey Abrams; Jennifer L Stevens; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2006-02-20 Impact factor: 44.544
Authors: Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Lori A Pollack; A Blythe Ryerson; Kevin C Ward Journal: Breast Cancer Res Treat Date: 2012-01-26 Impact factor: 4.872
Authors: Diana S M Buist; Jaclyn L F Bosco; Rebecca A Silliman; Heather Taffet Gold; Terry Field; Marianne Ulcickas Yood; Virginia P Quinn; Marianne Prout; Timothy L Lash Journal: Breast Cancer Res Treat Date: 2013-10-11 Impact factor: 4.872
Authors: David S Carrell; Scott Halgrim; Diem-Thy Tran; Diana S M Buist; Jessica Chubak; Wendy W Chapman; Guergana Savova Journal: Am J Epidemiol Date: 2014-01-30 Impact factor: 4.897
Authors: Reina Haque; Ninah S Achacoso; Suzanne W Fletcher; Larissa Nekhlyudov; Laura C Collins; Stuart J Schnitt; Charles P Quesenberry; Laurel A Habel Journal: Am J Manag Care Date: 2010-05 Impact factor: 2.229
Authors: Thomas Delate; Erin J Aiello Bowles; Roy Pardee; Robert D Wellman; Laurel A Habel; Marianne Ulcickas Yood; Larissa Nekhlyudov; Katrina A Goddard; Robert L Davis; Catherine A McCarty; Adedayo A Onitilo; Heather Spencer Feigelson; Jared Freml; Edward Wagner Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-15 Impact factor: 4.254
Authors: Gery P Guy; Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Kevin C Ward Journal: Health Serv Res Date: 2014-12-10 Impact factor: 3.402
Authors: Aruna Kamineni; Melissa L Anderson; Emily White; Stephen H Taplin; Peggy Porter; Rachel Ballard-Barbash; Kathleen Malone; Diana S M Buist Journal: Cancer Causes Control Date: 2012-12-07 Impact factor: 2.506
Authors: Mark Hwang; Mishel Farasatpour; Campbell D Williams; Julie A Margenthaler; Katherine S Virgo; Frank E Johnson Journal: Oncol Lett Date: 2012-01-09 Impact factor: 2.967
Authors: Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu Journal: Breast Cancer Res Treat Date: 2020-09-14 Impact factor: 4.872